Pfizer Inc. (NYSE:PFE) Shares Sold by Certuity LLC

Certuity LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 0.5% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 150,035 shares of the biopharmaceutical company’s stock after selling 775 shares during the quarter. Certuity LLC’s holdings in Pfizer were worth $3,802,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the stock. William B. Walkup & Associates Inc. increased its stake in shares of Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock valued at $1,044,000 after purchasing an additional 454 shares in the last quarter. Members Trust Co increased its stake in shares of Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 467 shares in the last quarter. Sutton Place Investors LLC increased its stake in shares of Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock valued at $224,000 after purchasing an additional 472 shares in the last quarter. Bellevue Group AG increased its stake in shares of Pfizer by 0.3% in the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company’s stock valued at $3,756,000 after purchasing an additional 485 shares in the last quarter. Finally, MSH Capital Advisors LLC increased its stake in shares of Pfizer by 1.4% in the 1st quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock valued at $876,000 after purchasing an additional 485 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 2.0%

NYSE:PFE opened at $25.14 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock’s fifty day moving average is $24.52 and its two-hundred day moving average is $24.47. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The stock has a market capitalization of $142.93 billion, a price-to-earnings ratio of 13.37, a price-to-earnings-growth ratio of 0.88 and a beta of 0.52.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the prior year, the firm earned $0.60 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s dividend payout ratio is currently 91.49%.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Morgan Stanley boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Wolfe Research boosted their price objective on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research note on Wednesday, April 30th. Redburn Atlantic lowered their target price on Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. Finally, UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.